Roche Holding AG Share Price Börse Stuttgart

Equities

RHO

CH0012032113

Pharmaceuticals

Delayed Börse Stuttgart 14:43:21 28/06/2019 BST 5-day change 1st Jan Change
245 EUR -0.08% Intraday chart for Roche Holding AG -2.62% +15.68%

Financials

Sales 2024 * 60.06B 66.26B 60.96B 5,231B Sales 2025 * 63.61B 70.18B 64.57B 5,540B Capitalization 190B 209B 192B 16,508B
Net income 2024 * 13.41B 14.8B 13.61B 1,168B Net income 2025 * 14.87B 16.4B 15.09B 1,295B EV / Sales 2024 * 3.38 x
Net Debt 2024 * 13.75B 15.17B 13.96B 1,198B Net Debt 2025 * 7.73B 8.53B 7.85B 673B EV / Sales 2025 * 3.1 x
P/E ratio 2024 *
13.7 x
P/E ratio 2025 *
12.5 x
Employees -
Yield 2024 *
4.14%
Yield 2025 *
4.28%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 49 31/12/02
Chairman 57 31/12/07
Director of Finance/CFO 57 31/03/11
Members of the board TitleAgeSince
Director/Board Member 72 02/03/15
Director/Board Member 59 -
Director/Board Member 66 31/12/95
More insiders
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Calendar
22/05/2024 - Investor Day
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
234.8 CHF
Average target price
279.4 CHF
Spread / Average Target
+18.99%
Consensus